ReShape Lifesciences Inc (NASDAQ:RSLS) has a beta value of 1.44 and has seen 3.89 million shares traded in the recent trading session. The company, currently valued at $0.82M, closed the recent trade at $1.13 per share which meant it lost -$1.2 on the day or -51.50% during that session. The RSLS stock price is -2466.37% off its 52-week high price of $29.00 and -105.31% below the 52-week low of $2.32. If we look at the company’s 10-day average daily trading volume, we find that it stood at 89030.0 shares traded. The 3-month trading volume is 38.27K shares.
The consensus among analysts is that ReShape Lifesciences Inc (RSLS) is Buy stock at the moment, with a recommendation rating of 1.00. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 1 have rated it as a Hold, with 1 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is 0.
ReShape Lifesciences Inc (NASDAQ:RSLS) trade information
Sporting -51.50% in the red today, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the RSLS stock price touched $1.13 or saw a rise of 61.56%. Year-to-date, ReShape Lifesciences Inc shares have moved -74.66%, while the 5-day performance has seen it change -59.80%. Over the past 30 days, the shares of ReShape Lifesciences Inc (NASDAQ:RSLS) have changed -75.80%. Short interest in the company has seen 22551.0 shares shorted with days to cover at 0.91.
ReShape Lifesciences Inc (RSLS) estimates and forecasts
The company’s shares have lost -88.94% over the past 6 months.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 76.96% over the past 5 years.
RSLS Dividends
ReShape Lifesciences Inc is expected to release its next earnings report in March this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
ReShape Lifesciences Inc (NASDAQ:RSLS)’s Major holders
Insiders own 8.64% of the company shares, while shares held by institutions stand at 4.10% with a share float percentage of 4.48%. Investors are also buoyed by the number of investors in a company, with ReShape Lifesciences Inc having a total of 10.0 institutions that hold shares in the company.
Also the top two Mutual Funds that are holding company’s shares are Fidelity Extended Market Index Fund and Vanguard Extended Market Index Fund. As of Nov 30, 2024, the former fund manager holds about 0.33% shares in the company for having 2.42 shares of worth $2612.0 while later fund manager owns 860.0 shares of worth $929.0 as of Sep 30, 2024, which makes it owner of about 0.12% of company’s outstanding stock.
